Former BeiGene Executive Committee Member Dr. Jian Liu Joins Guangzhou Pharmaceutical Group as Chief Strategic Scientist

Source: Shanghai Securities News · China Securities Network

Shanghai Securities News China Securities Network (Reporter Li Wuqiang): Recently, Guangzhou Pharmaceutical Holdings Limited announced that Dr. Liu Jian has joined the company as its Strategic Scientist, marking the addition of another leading figure with both international vision and practical industry experience to Guangzhou Pharmaceutical Holdings Limited.

Liu Jian has extensive experience in the research and development of biologics, industrialization, and multinational corporate management. Prior to joining Guangzhou Pharmaceutical Holdings Limited, Liu Jian served asBeOneMember of the Global Executive Committee, CEO of the Innovation Center, and Chairman of Biologics at BeOne, Mr. Liu Jian has led the innovative drug incubation initiatives at BeOne’s Innovation Center, translating cutting-edge scientific concepts into high-quality commercial assets, and spearheaded the construction of BeOne’s biologics manufacturing base in Guangzhou. With extensive experience in new drug development, investment and financing management, and pharmaceutical distribution at Pfizer, Sanofi, AstraZeneca, Novartis, and Johnson & Johnson Pharmaceuticals, Mr. Liu is a seasoned expert and executive in the innovative pharmaceutical industry.

Upon assuming the role of Strategic Scientist at Guangzhou Pharmaceutical Holdings Limited, Liu Jiancheng will become a core member of the company’s strategic development for innovation-driven transformation. Leveraging his profound insights into the global biopharmaceutical landscape and extensive industry experience, he will spearhead initiatives in tackling major diseases, establishing innovative drug pipelines, and facilitating the commercialization of scientific and technological achievements.

Li Xiaojun, Party Secretary and Chairman of Guangzhou Pharmaceutical Holdings Limited, stated that the addition of Liu Jian marks a milestone in the Group’s recruitment of high-level talent and will significantly enhance its top-level design capabilities and strategic execution in the biopharmaceutical sector.